New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
11:15 EDTQUREuniQure announces analysis of six-year follow-up data for Glybera
uniQure announced the full analysis of the six-year follow-up data for patients treated once with Glybera, uniQure's gene therapy product for the treatment of lipoprotein lipase deficiency. Glybera is approved in the EU as a treatment for LPLD, a potentially life-threatening, orphan metabolic disease that results in patients' inability to process fat in the blood after a meal. LPLD patients eligible for Glybera treatment suffer from reoccurring and often severe pancreatitis events leading to recurrent admissions to hospitals and intensive care units.
News For QURE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 7, 2015
13:44 EDTQURE to host investor day
Subscribe for More Information
October 5, 2015
10:19 EDTQURESpark trial success a positive for gene therapy sector, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said he views the news that Spark Therapeutics (ONCE) "highly anticipated" SPK-RPE65 Phase 3 gene therapy study for congenital blindness met its primary endpoint as a positive for the ophthalmology gene therapy field as well as the broader gene therapy sector. Schimmer added that Applied Genetic Technologies' (AGTC) early clinical data in the second half of this year will be a further test of the ophthalmology gene therapy platform. The analyst noted that other companies with gene therapy programs include Avalanche (AAVL), Biogen (BIIB), bluebird bio (BLUE), BioMarin (BMRN), Cellectis (CLLS), Medgenics (MDGN), uniQure (QURE), Pfizer (PFE), Regeneron (REGN) and Sangamo (SGMO).
September 28, 2015
09:19 EDTQUREuniQure weakness creates buying opportunity, says Roth Capital
Noting that uniQure has sold off amid worries about the high cost of its gene therapy, Roth Capital says that uniQure's gene therapy is less costly than the current lifetime treatment regimen for hemophiliacs. The firm thinks that the sell-off in the stock has created a buying opportunity for long-term investors. It keeps a $38 price target and Buy rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use